DE69816835T2 - Inhibitoren der nuklearen lokalisierung von hiv - Google Patents

Inhibitoren der nuklearen lokalisierung von hiv Download PDF

Info

Publication number
DE69816835T2
DE69816835T2 DE69816835T DE69816835T DE69816835T2 DE 69816835 T2 DE69816835 T2 DE 69816835T2 DE 69816835 T DE69816835 T DE 69816835T DE 69816835 T DE69816835 T DE 69816835T DE 69816835 T2 DE69816835 T2 DE 69816835T2
Authority
DE
Germany
Prior art keywords
hiv
compound
methyl
amino
branched
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE69816835T
Other languages
German (de)
English (en)
Other versions
DE69816835D1 (de
Inventor
Senliang Pan
Michael Bukrinsky
K. Omar HAFFAR
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Picower Institute for Medical Research
Original Assignee
Picower Institute for Medical Research
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Picower Institute for Medical Research filed Critical Picower Institute for Medical Research
Application granted granted Critical
Publication of DE69816835D1 publication Critical patent/DE69816835D1/de
Publication of DE69816835T2 publication Critical patent/DE69816835T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/47—One nitrogen atom and one oxygen or sulfur atom, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/48—Two nitrogen atoms

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Virology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • AIDS & HIV (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
DE69816835T 1997-08-15 1998-08-13 Inhibitoren der nuklearen lokalisierung von hiv Expired - Fee Related DE69816835T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US912076 1997-08-15
US08/912,076 US5808068A (en) 1997-08-15 1997-08-15 HIV nuclear localization inhibitors
PCT/US1998/016814 WO1999009014A1 (en) 1997-08-15 1998-08-13 Hiv nuclear localization inhibitors

Publications (2)

Publication Number Publication Date
DE69816835D1 DE69816835D1 (de) 2003-09-04
DE69816835T2 true DE69816835T2 (de) 2004-04-22

Family

ID=25431342

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69816835T Expired - Fee Related DE69816835T2 (de) 1997-08-15 1998-08-13 Inhibitoren der nuklearen lokalisierung von hiv

Country Status (8)

Country Link
US (1) US5808068A (https=)
EP (1) EP1012146B1 (https=)
JP (1) JP4475487B2 (https=)
AT (1) ATE245983T1 (https=)
AU (1) AU758464B2 (https=)
CA (1) CA2300424C (https=)
DE (1) DE69816835T2 (https=)
WO (1) WO1999009014A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6297253B1 (en) * 1996-10-15 2001-10-02 The Picower Institute For Medical Research Compounds and methods of use to treat infectious diseases
CA2686618A1 (en) * 2003-07-17 2005-01-17 At&T Corp. Method and apparatus for windowing in entropy encoding
US20050203150A1 (en) * 2004-03-09 2005-09-15 Haffar Omar K. Compounds, compositions and methods for inhibiting or treating HIV-1

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0673022A (ja) * 1992-08-27 1994-03-15 Kumiai Chem Ind Co Ltd ピリミジンまたはトリアジン誘導体及び除草剤

Also Published As

Publication number Publication date
JP4475487B2 (ja) 2010-06-09
CA2300424C (en) 2009-04-07
WO1999009014A1 (en) 1999-02-25
EP1012146A1 (en) 2000-06-28
EP1012146A4 (en) 2002-12-04
EP1012146B1 (en) 2003-07-30
DE69816835D1 (de) 2003-09-04
ATE245983T1 (de) 2003-08-15
JP2001515069A (ja) 2001-09-18
US5808068A (en) 1998-09-15
AU758464B2 (en) 2003-03-20
AU8905498A (en) 1999-03-08
CA2300424A1 (en) 1999-02-25

Similar Documents

Publication Publication Date Title
DE69633398T2 (de) Betulinsäure-derivate und ihre verwendungen
DE69934486T2 (de) Acylierte betulin- und dihydrobetulinderivate, ihre herstellung und verwendung
DE69709857T2 (de) Acridonderivate als antineoplastische-und antiretrovirale mittel
SE450251B (sv) Xantatforeningar for terapeutisk anvendning, nya xantatforeningar samt terapeutiska kompositioner innehallande dessa foreningar
US5703086A (en) Compounds and methods of use to derivatize neighboring lysine residues in proteins under physiological conditions
DE68910211T2 (de) Estramustin-ester.
DE69416683T2 (de) Benzolactam-derivate
DE69119700T2 (de) Verwendung von Xanthinen zur Herstellung von Arzneimitteln zur Hemmung der Vermehrung menschlicher Retroviren
DE69816835T2 (de) Inhibitoren der nuklearen lokalisierung von hiv
EP0314011A2 (de) Purinderivate
DE2438399A1 (de) Neue, alpha-substituierte benzhydrolderivate und ein verfahren zu ihrer herstellung
AU759210B2 (en) HIV matrix protein tyrosine position 29 pocket binders
DE19703763C1 (de) Thalidomidanaloge Verbindungen aus der Klasse der Piperidin-2,6-Dione
DE2833986C2 (https=)
EP0349928A2 (de) Purinderivate
DE2923698A1 (de) Substituierte aminoalkansaeuren, ihre verwendung und herstellung und sie enthaltende arzneimittel
US5574040A (en) Pyrimidine compounds and methods of use to derivatize neighboring lysine residues in proteins under physiologic conditions
NL8403181A (nl) 4-chloorfuro(3,4-c)pyridinederivaten, werkwijzen ter bereiding ervan en farmaceutische preparaten, die hen bevatten.
EP0454060A1 (de) 3-(Mercaptoalkyl)-chinazolin-2,4(1H,3H)-dione, Verfahren zu ihrer Herstellung und pharmazeutische Zubereitungen
US3303095A (en) Compositions and methods for producing tranquilizing activity
DE4021006A1 (de) Pyrimidin-derivate, deren herstellung und verwendung sowie diese enthaltende arzneimittel
EP0557877A1 (de) Lösliche Salze von 4-Amino-2-(4,4-dimethyl-imidazolidin-2-on-1-yl)-pyrimidin-5 -carbonsäure- N-methyl-N-(3-trifluormethyl-phenyl)- amid, Verfahren zu ihrer Herstellung, ihre Verwendung als Arzneimittel und Ausgangsprodukte
DE2624856A1 (de) 2-thiohexahydropyrimidin-4,6-dion-derivate und verfahren zu ihrer herstellung
DE69006187T2 (de) Verwendung von Chinolyl- und Isochinolyloxazol-2-onen zur Herstellung eines Arzneimittels zur Verhinderung der Ansteckungsfähigkeit von mit Glykoproteinen umhüllten Viren.
EP0280017A1 (de) Neue Isoxazolderivate, Verfahren zu ihrer Herstellung und diese enthaltende pharmazeutische Präparate

Legal Events

Date Code Title Description
8339 Ceased/non-payment of the annual fee